Next Generation Sequencing (NGS) for Diagnosis and Therapy of Patients with Cancer and Hematological Malignancies

Overview

About this study

The purpose of this study is to test a new technology called Next Generation Sequencing (NGS) that may help identify potential therapies for certain cancer. NGS is a procedure that looks at all genes. Right now, NGS is only done in outside labs.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients must have a  histological or cytological confirmation of a malignancy.
  • Patient must have a life expectancy >3 months.
  • Patient is a candidate for a  core biopsy or surgical procedure to obtain tissue, or there is a quality tissue sample available from which DNA and RNA can be obtained.
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures, or have a parent/legal guardian able to do so. 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Robert McWilliams, M.D.

Closed for enrollment

Jacksonville, Fla.

Mayo Clinic principal investigator

Robert McWilliams, M.D.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Robert McWilliams, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20493003

Mayo Clinic Footer